undamentalytics Newsletter
Sign in

Viemed Healthcare, Inc. (VMD) stock

Add to watchlist

Add holding +

NASDAQ: VMD Nasdaq Health Care Services Next results ~November 4, 2026

B Fundamentals grade

Viemed Healthcare, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$4.9

Cash-flow model

Base case. Range ~$3.7–$6.4 across our lower- and higher-growth cases (15%–25% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 48% below it.

Price used: $9.44, November 2, 2026

Viemed Healthcare, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 9 sales by directors and officers, last 12 monthsInsider trades
  • Funds100 adding, 45 cuttingOf 28 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Viemed Healthcare files

Where Viemed Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $302m, up 25.2% on a year earlier, faster than the 23.1% growth a quarter earlier. Free-cash-flow margin rose to 9.7% from -1.5% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 7 of our 7 financial-health checks. Our cash-flow model value is $4.89 a share, against a share price of $10.18.

Source: 10-Q filed August 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Viemed Healthcare, Inc.'s trailing-twelve-month revenue grew 25.2% year on year, with a free-cash-flow margin of 9.7%. Where it stands out: long-term debt as % of assets of 3.1% ranks 4 of 31 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$4.9 per share in the base case (~$3.7–$6.4 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 25.2% (+2.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 25.2% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Shrinking share count. Diluted shares fell 1.6% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Priced above our value. The share price of $9.44 is 48% above our value per share of $5.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 10.9% over 90 days.

Latest results: FY2026 Q2

Filed August 3, 2026
Earnings per share
$0.07 against an average estimate of $0.10: missed by 30.0%
Revenue
$78m, up 23.9% on a year earlier
Share reaction
-15.7% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 4, 2026

Viemed Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.4%
  • 1 week-3.0%
  • 1 month+3.4%
  • This year+27.1%
  • 1 year+46.1%
  • 5 years+62.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$302M
Operating margin
7.5%
Net margin
4.8%
EPS (TTM, diluted)
$0.36

Growth

Revenue growth
+25.2%
Change in growth rate
+2.1 pts
Share count change
−1.6%

Cash

Free cash flow (TTM)
$29.2M
FCF margin
9.7%
Stock pay % of revenue
3.0%

Earnings

Last results
August 3, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Viemed Healthcare, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 31.1% a year of cash-flow growth for five years.That is faster than the 20.8% a year revenue growth Viemed Healthcare has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in31.1%
  • Last 12 months25.2%
  • 3 years a year24.5%
  • 5 years a year20.8%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($9.42, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$4.9
Price used
$9.42close November 3, 2026
Implied change
▼ 48%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Viemed Healthcare, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($4.4M, FY2026 Q2 TTM), growing 14.8% and 17.9% in the next two years (forecasts, guidance and its record), then back to 20% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$3.7–~$6.4 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Viemed Healthcare, Inc.'s free cash flow after stock-based pay ( $4.4M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Viemed Healthcare, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.65 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$4.9 ~$3.7–$6.4 Primary model, counts double
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.3 ~$5.1–$9.0 Included
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.8 ~$7.8–$15 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$4.7 ~$3.0–$7.6 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$4.9 ~$4.0–$6.1 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.1 ~$4.7–$9.8 5 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Viemed Healthcare, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −24%
  • Revenue growth 5 points higher ▲ +30%
  • Free-cash-flow margin 1 point lower ▼ −10%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $2$2$3$4$6$7
8.5% $1$2$2$3$4$5
10% $1$1$2$2$3$4

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$6.20$7.76$5.22$7.56$7.85$8.02$7.43$9.44
Market value$246m$314m$212m$301m$317m$327m$303m$383m
+ Net debt (− = net cash)−$4m−$23m−$23m−$17m−$6m−$14m−$1m−$4m
Enterprise value$242m$291m$190m$284m$311m$314m$302m$379m
Multiples
Price / sales 3.1x2.4x1.8x2.2x1.7x1.5x1.1x1.3x
Price / earnings 28.9x10.0x23.3x48.4x30.9x29.1x20.3x26.4x
Price / free cash flow 43.2x14.3x77.2x62.1x16.6xn/m25.4x13.1x
EV / EBITDA 15.9x8.0x8.3x11.9x8.6x7.3x5.9x9.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

62 /100

Moderate moat

How hard Viemed Healthcare's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 11 / 20

    Net income has been a median 7.5% of total assets over 8 years.

  • Pricing power 17 / 20

    Gross margin has been a median 61.2%, moving by 4.6 percentage points (standard deviation) across 8 years.

  • Durability 12 / 20

    Operating margin has been a median 8.6%; its worst year was 6.3%.

  • Cash conversion 13 / 20

    Free cash flow was positive in 7 of 8 years, at a median 7.5% of revenue.

  • Discipline 15 / 20

    The diluted share count fell 1.0% over five years; stock-based pay has been a median 3.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (67 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $81m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.41 +12% $318m +18%
Next $0.54 +31% $354m +11%

Next year's EPS estimate has moved −10.9% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −9.2% on 90 days ago. In the last 30 days, 0 analysts raised Viemed Healthcare, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Viemed Healthcare, Inc., last 90 days
$0.40 $0.45 $0.50 $0.55 $0.60 $0.65 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.46 Current fiscal year, 60 days ago: $0.41 Current fiscal year, 30 days ago: $0.41 Current fiscal year, 7 days ago: $0.41 Current fiscal year, Now: $0.41 $0.41 Next fiscal year, 90 days ago: $0.61 Next fiscal year, 60 days ago: $0.54 Next fiscal year, 30 days ago: $0.54 Next fiscal year, 7 days ago: $0.54 Next fiscal year, Now: $0.54 $0.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.46$0.61
60 days ago $0.41$0.54
30 days ago $0.41$0.54
7 days ago $0.41$0.54
Now $0.41$0.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.10 $0.07 −30.0%
Mar 2026 $0.09 $0.06 −33.3%
Dec 2025 $0.13 $0.14 +12.0%
Sept 2025 $0.09 $0.09 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Viemed Healthcare, Inc.'s revenue by +14.8% next year and +17.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+11.3%, weight 60%) and the company's own record (+20.0%, weight 40%) . How the weights are set.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026112

Counts of recommendations published by analysts covering Viemed Healthcare, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.7%
of tradable shares
Days to cover
5.97
at average volume
Short interest, 1 month
+16%
to October 15, 2026
Held by institutions
71%
of shares
Held by insiders
13.9%
of shares
Employees
1,438
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +46.1%

$6.46 on October 31, 2025 to $9.44

ThenNowEffect
Revenue (last 12 months) $241m $302m +25.2%
Net margin 5.8% 4.8% −17.1%
P/E multiple 19.0x 26.4x +38.6%
Share count 41m 41m +1.6%

Biggest factor: p/e multiple.

Last 3 years +26.2%

$7.48 on November 3, 2023 to $9.44

ThenNowEffect
Revenue (last 12 months) $156m $302m +93.2%
Net margin 4.7% 4.8% +2.3%
P/E multiple 40.7x 26.4x −35.1%
Share count 40m 41m −1.5%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VMD−33%+45%+4%+2%−7%+27%
Industry peers (median)−1%−28%+8%−6%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VMD42%58%58%58%42%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VMD−54%−36%−49%−37%−30%−31%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 9, 2019: 69% from June 22, 2020 to March 7, 2022. Getting back needed a 226% gain, reached on April 21, 2023, 410 days after the low.

Price behaviour

52-week range
$6.26 – $12.33
From 52-week high
−23.4%
vs 50-day average
+2.2%
vs 200-day average
−1.4%
Volatility (1 year)
39%
Beta vs S&P 500
0.23

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±8.0%
After a week
7 up, 5 down
typical move ±7.0%
After a month
6 up, 6 down
typical move ±9.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 −15.7% +3.3% −20.1% −24.6%
May 5, 2026 −10.2% +2.2% −1.3% +3.8%
March 4, 2026 −6.1% +0.1% +1.5% +7.6%
November 5, 2025 −4.3% −0.7% +0.2% +3.5%
August 6, 2025 +10.1% +0.7% +16.0% +8.9%
May 7, 2025 −13.2% +1.1% −7.2% −9.2%
March 10, 2025 +4.0% −3.5% −1.2% −11.2%
November 6, 2024 +2.3% +3.3% +4.0% −2.0%
August 7, 2024 +6.2% +1.6% +4.9% +8.4%
May 6, 2024 −6.4% +1.1% −13.8% −7.7%
March 6, 2024 +9.4% +1.5% +3.8% −6.9%
November 1, 2023 +7.8% +3.0% +10.0% +21.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Viemed Healthcare, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Viemed Healthcare, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Viemed Healthcare, Inc.
$150M $200M $250M $300M $350M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $169.8M Revenue (TTM), FY23 Q4: $183M Revenue (TTM), FY24 Q1: $194M Revenue (TTM), FY24 Q2: $205.7M Revenue (TTM), FY24 Q3: $214.3M Revenue (TTM), FY24 Q4: $224.3M Revenue (TTM), FY25 Q1: $232.8M Revenue (TTM), FY25 Q2: $240.9M Revenue (TTM), FY25 Q3: $254.8M Revenue (TTM), FY25 Q4: $270.3M Revenue (TTM), FY26 Q1: $286.6M Revenue (TTM), FY26 Q2: $301.6M $301.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $169.8M
FY23 Q4 $183M
FY24 Q1 $194M
FY24 Q2 $205.7M
FY24 Q3 $214.3M
FY24 Q4 $224.3M
FY25 Q1 $232.8M
FY25 Q2 $240.9M
FY25 Q3 $254.8M
FY25 Q4 $270.3M
FY26 Q1 $286.6M
FY26 Q2 $301.6M
Revenue growth, TTM YoY Viemed Healthcare, Inc.
15% 20% 25% 30% 35% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 27.4% Revenue growth, TTM YoY, FY23 Q4: 31.8% Revenue growth, TTM YoY, FY24 Q1: 32.8% Revenue growth, TTM YoY, FY24 Q2: 31.7% Revenue growth, TTM YoY, FY24 Q3: 26.2% Revenue growth, TTM YoY, FY24 Q4: 22.5% Revenue growth, TTM YoY, FY25 Q1: 20.0% Revenue growth, TTM YoY, FY25 Q2: 17.1% Revenue growth, TTM YoY, FY25 Q3: 18.9% Revenue growth, TTM YoY, FY25 Q4: 20.5% Revenue growth, TTM YoY, FY26 Q1: 23.1% Revenue growth, TTM YoY, FY26 Q2: 25.2% 25.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 27.4%
FY23 Q4 31.8%
FY24 Q1 32.8%
FY24 Q2 31.7%
FY24 Q3 26.2%
FY24 Q4 22.5%
FY25 Q1 20.0%
FY25 Q2 17.1%
FY25 Q3 18.9%
FY25 Q4 20.5%
FY26 Q1 23.1%
FY26 Q2 25.2%
Operating margin (TTM) Viemed Healthcare, Inc.
7% 7.5% 8% 8.5% 9% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 7.4% Operating margin (TTM), FY23 Q4: 7.8% Operating margin (TTM), FY24 Q1: 7.5% Operating margin (TTM), FY24 Q2: 7.4% Operating margin (TTM), FY24 Q3: 7.8% Operating margin (TTM), FY24 Q4: 8.0% Operating margin (TTM), FY25 Q1: 8.4% Operating margin (TTM), FY25 Q2: 8.7% Operating margin (TTM), FY25 Q3: 8.3% Operating margin (TTM), FY25 Q4: 8.5% Operating margin (TTM), FY26 Q1: 8.2% Operating margin (TTM), FY26 Q2: 7.5% 7.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 7.4%
FY23 Q4 7.8%
FY24 Q1 7.5%
FY24 Q2 7.4%
FY24 Q3 7.8%
FY24 Q4 8.0%
FY25 Q1 8.4%
FY25 Q2 8.7%
FY25 Q3 8.3%
FY25 Q4 8.5%
FY26 Q1 8.2%
FY26 Q2 7.5%
FCF margin (TTM) Viemed Healthcare, Inc.
-5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 9.4% FCF margin (TTM), FY23 Q4: 10.4% FCF margin (TTM), FY24 Q1: 4.4% FCF margin (TTM), FY24 Q2: 4.0% FCF margin (TTM), FY24 Q3: 1.6% FCF margin (TTM), FY24 Q4: 0.6% FCF margin (TTM), FY25 Q1: -2.8% FCF margin (TTM), FY25 Q2: -1.5% FCF margin (TTM), FY25 Q3: 2.1% FCF margin (TTM), FY25 Q4: 4.4% FCF margin (TTM), FY26 Q1: 9.0% FCF margin (TTM), FY26 Q2: 9.7% 9.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 9.4%
FY23 Q4 10.4%
FY24 Q1 4.4%
FY24 Q2 4.0%
FY24 Q3 1.6%
FY24 Q4 0.6%
FY25 Q1 -2.8%
FY25 Q2 -1.5%
FY25 Q3 2.1%
FY25 Q4 4.4%
FY26 Q1 9.0%
FY26 Q2 9.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Viemed Healthcare took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $270M
  2. Cost of revenue $115M · 42.5%
  3. Gross profit $155M · 57.5%
  4. Research and development $3M · 1.1%
  5. Selling, general and admin $121M · 44.9%
  6. Other operating costs $8.1M · 3.0%
  7. Operating income $22.9M · 8.5%
  8. Income tax $6.4M · 2.4%
  9. Interest and other $1.6M · 0.6%
  10. Net income $14.9M · 5.5%

Shares of revenue. Source: Viemed Healthcare's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 64 80 131 117 139 183 224 270 302
Gross profit 48 56 80 73 85 113 133 155 173
EBITDA 14 15 36 23 24 36 43 52 39
Operating income 10 9 27 12 8 14 18 23 23
Net income 10 9 32 9 6 10 11 15 14
Diluted EPS $0.24 $0.21 $0.78 $0.22 $0.16 $0.25 $0.28 $0.37 $0.36
Growth (year on year)
Revenue — +24.5% +63.6% −10.8% +18.6% +31.8% +22.5% +20.5% +25.2%
EBITDA — +10.2% +138.3% −37.0% +4.3% +51.5% +19.6% +19.2% +11.7%
Operating income — −11.9% +202.4% −56.8% −28.7% +73.7% +24.9% +28.2% +8.3%
Net income — −10.3% +269.9% −71.1% −31.8% +64.6% +10.0% +32.6% +3.7%
Diluted EPS — −12.5% +271.4% −71.8% −27.3% +56.3% +12.0% +32.1% +5.4%
Margins
Gross margin 74.1% 69.8% 61.0% 62.7% 61.0% 61.6% 59.4% 57.5% 57.5%
EBITDA margin 21.5% 19.0% 27.7% 19.6% 17.2% 19.8% 19.3% 19.1% 12.8%
Operating margin 15.6% 11.0% 20.4% 9.9% 5.9% 7.8% 8.0% 8.5% 7.5%
Net margin 14.7% 10.6% 24.0% 7.8% 4.5% 5.6% 5.0% 5.5% 4.8%
Free-cash-flow margin 25.2% 7.1% 16.8% 2.4% 3.5% 10.4% 0.6% 4.4% 9.7%
Cash flow
Cash from operations 22 19 35 22 28 45 39 52 61
Capital spending 6 13 13 20 23 26 38 40 32
Free cash flow 16 6 22 3 5 19 1 12 29
Stock-based pay 3 4 5 5 5 6 6 9 9
Free cash flow after stock pay 14 2 17 −2 −0 13 −5 3 20
Balance sheet
Cash 10 13 31 28 17 13 18 14 11
Total debt 0 9 8 6 0 7 4 12 7
Net debt (negative = net cash) −10 −4 −23 −23 −17 −6 −14 −1 −4
Diluted shares 40m 40m 41m 41m 40m 40m 41m 41m 41m
Returned to shareholders
Buybacks 2 2 0 0 10 0 0 13 18
Total returned 2 2 0 0 10 0 0 13 18

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

7 of 7 checks passed · June 30, 2026
What it owns · $204m
Short-term assets $54mLonger-term assets $150m
What it owes, and who funded it · $202m
Short-term liabilities $48mLonger-term liabilities $10mShareholders' equity $144m
  • Short-term assets cover short-term liabilities $54m of assets due within a year against $48m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $54m short-term assets against $10m of longer-dated liabilities.
  • More cash than debt $11m of cash against $7m of debt.
  • Debt below 40% of shareholders' equity Debt is 5% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 5% to 5% over five years.
  • A year's operating cash flow covers at least 20% of debt $61m of operating cash flow against $7m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Viemed Healthcare, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$18.3M
Returned to shareholders
63%
of free cash flow
Buybacks, last 3 fiscal years
$13.2M
Diluted share count
−1.6%
year over year
Total shareholder yield
5.1%
dividends 0.0% + buybacks 5.1% of market value
R&D spending
0.8%
of revenue
Sales & admin spending
45.1%
of revenue
Days sales outstanding
39 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated VMD DCGO DLHC CDNA SBC PETS Median
Revenue, last 12 months $302m $295m $254m $497m $175m $169m $1.2bn
Revenue growth, last 12 months 25.2% −32.4% −29.5% 38.9% −6.9% −20.3% 7.3%
Revenue growth, 3-year average 24.5% −13.3% −9.5% 18.7% — −13.0% 11.3%
Revenue growth, latest quarter 23.9% −8.7% −46.9% 39.3% 13.4% −19.9% 8.5%
Gross margin 57.5% — 24.3% 65.5% 71.9% 27.9% 27.9%
Operating margin 7.5% −62.2% −0.1% 23.4% 37.3% −18.2% 2.3%
Operating margin, 3-year average 7.9% −20.8% 3.5% −4.4% 37.3% −12.6% 2.3%
Net margin 4.8% −65.3% −8.5% 25.9% 28.0% −17.3% 1.2%
Cash from operations / revenue 20.2% −7.7% 5.5% 13.9% 35.9% −14.1% 6.1%
Free-cash-flow margin 9.7% −8.8% 5.5% 10.3% 35.3% −16.4% 5.1%
Free-cash-flow margin, 3-year average 4.1% 1.4% 6.6% 5.3% — −7.3% 3.6%
Stock pay / revenue 3.0% 4.6% 0.5% 7.7% — 0.6% 1.1%
Change in share count −1.6% −7.1% 2.2% −9.3% 1.4% 2.9% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 25.2% 7.3% 9 of 41
Change in growth rate Growth +2.1pp +1.1pp 17 of 41
Gross margin Profitability 57.5% 29.0% 6 of 27
Operating margin Profitability 7.5% 2.6% 13 of 40
Net margin Profitability 4.8% 1.2% 12 of 41
Free-cash-flow margin Cash generation 9.7% 5.1% 12 of 40
Stock pay as % of revenue Cash generation 3.0% 0.9% 26 of 35
Long-term debt as % of assets Balance sheet 3.1% 27.7% 4 of 31
Change in share count Balance sheet -1.6% 0.4% 12 of 39
Days sales outstanding Balance sheet 39 days 39 days 16 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Equipment Sales $50.3M ▲ 62.7%
Services $24.9M ▲ 23.6%

These categories overlap or exclude eliminations, so shares aren't shown.

From Viemed Healthcare, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$310M
Institutions reporting
165
Shares held vs prior quarter
▲ 9.1%
Positions opened / closed
28 / 11

Top buyers and sellers, Q2 2026: 100 institutions bought and 45 sold ; the biggest buyer was First Eagle Investment Management, LLC (+541K shares) and the biggest seller Forager Capital Management, LLC (−685K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $54.6M 4.8M 17.6% ▲ 3.6%
Forager Capital Management, LLC $24.4M 2.1M 7.9% ▼ 24.2%
Vanguard Capital Management LLC $15.1M 1.3M 4.9% ▲ 1.4%
Nantahala Capital Management, LLC $14.4M 1.3M 4.7% ▲ 43.1%
Goldman Sachs Group Inc $13.9M 1.2M 4.5% ▼ 14.0%
First Eagle Investment Management, LLC $12.2M 1.1M 3.9% ▲ 102.1%
Ameriprise Financial Inc $11.5M 1.0M 3.7% ▲ 12.0%
Geode Capital Management, LLC $11.1M 974K 3.6% ▲ 24.9%
Raffles Associates LP $9.2M 807K 3.0% ▲ 95.2%
Arrowstreet Capital, Limited Partnership $9M 786K 2.9% ▲ 10.6%
State Street Corp $8.7M 762K 2.8% ▲ 2.6%
Panagora Asset Management Inc $6.1M 539K 2.0% ▲ 14.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Viemed Healthcare, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.6M 9 trades by 3 insiders · 0% under pre-set plans
Net ▼ $1.6M net selling
Insider Date Trade Shares Price Value
Frazier William Chief Medical Officer June 25, 2026 Sell 10,000 $11.72 $117,200
Smokoff Timothy Director June 24, 2026 Sell 5,000 $11.53 $57,650
Smokoff Timothy Director June 24, 2026 Sell 1,636 $11.48 $18,781
Smokoff Timothy Director June 24, 2026 Sell 5,000 $11.41 $57,050
Smokoff Timothy Director June 24, 2026 Sell 5,000 $11.56 $57,800
Smokoff Timothy Director June 24, 2026 Sell 3,364 $11.50 $38,686
Moore Michael President March 20, 2026 Sell 65,000 $8.77 $570,050
Moore Michael President March 19, 2026 Sell 40,232 $9.21 $370,537
Moore Michael President March 18, 2026 Sell 31,570 $9.42 $297,389

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 5, 2026
  • March 4, 2026
  • November 5, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Viemed Healthcare, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Viemed Healthcare, Inc. in brief

What does Viemed Healthcare, Inc. do?
Viemed Healthcare, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Viemed Healthcare, Inc.'s stock ticker?
Viemed Healthcare, Inc. trades under the ticker VMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Viemed Healthcare, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Viemed Healthcare, Inc. reported revenue of $302M, 25.2% higher than a year earlier, according to its SEC filings.
What is Viemed Healthcare, Inc.'s free cash flow?
Viemed Healthcare, Inc.'s free-cash-flow margin is 9.7% of revenue over the trailing twelve months, ranking 12 of the 40 health care services companies we cover.
What is Viemed Healthcare, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Viemed Healthcare, Inc.'s free cash flow after stock-based pay gives ~$4.9 per share in the base case, and ~$3.7–$6.4 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Viemed Healthcare, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Forager Capital Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Viemed Healthcare, Inc. buying back stock, and does it pay a dividend?
Viemed Healthcare, Inc. spent $18.3M on share repurchases over the trailing twelve months, and its diluted share count fell 1.6% over the year.
What is Viemed Healthcare, Inc.'s market cap?
On November 2, 2026, Viemed Healthcare, Inc.'s market capitalisation was about $383M, with a price-to-earnings ratio of 26.4 and net debt of -$3.6M. Market figures come from third-party market data and may be delayed.
How much debt does Viemed Healthcare, Inc. have?
Viemed Healthcare, Inc.'s debt-to-equity ratio is 4.9%, from its latest balance sheet (4.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Viemed Healthcare, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Viemed Healthcare, Inc. are Docgo Inc., DLH Holdings Corp., Caredx, Inc., SBC Medical Group Holdings Inc and Petmed Express Inc. The side-by-side comparison below sets their revenue, margins and growth against Viemed Healthcare, Inc.'s.
Are insiders buying or selling Viemed Healthcare, Inc. stock?
Over the last 12 months, Viemed Healthcare, Inc.'s directors and officers reported 0 open-market purchases and 9 sales on Form 4. The insider trading page charts every trade.
When is Viemed Healthcare, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Viemed Healthcare, Inc. announces its own schedule.